Abstract
The importance of T-cell-mediated antitumor immunity has been demonstrated in both animal models and human cancer therapy. The identification of major histocompatibility complex (MHC) class I-restricted tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, recent studies suggest that therapeutic strategies that have mainly focused on the use of CD8+ T cells (and MHC class I-restricted tumor antigens) may not be effective in eliminating cancer cells in patients. Novel strategies have been developed for enhancing T-cell responses against cancer by prolonging antigen presentation of dendritic cells to T cells and the inclusion of MHC class II-restricted tumor antigens. identification of MHC class II-restricted tumor antigens, which are capable of stimulating CD4+ T cells, not only aids our understanding of the host immune responses against cancer antigens, but also provides opportunities for developing effective cancer vaccines.
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antigen Presentation*
-
Antigens, Neoplasm / administration & dosage
-
Antigens, Neoplasm / immunology*
-
Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome
-
Base Sequence
-
CD4-Positive T-Lymphocytes / immunology*
-
Cancer Vaccines / pharmacokinetics*
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / immunology
-
Cell Membrane Permeability
-
Cytotoxicity, Immunologic
-
Dendritic Cells / immunology*
-
Histocompatibility Antigens Class II / immunology*
-
Humans
-
Lung Neoplasms / immunology
-
Lung Neoplasms / prevention & control
-
Lung Neoplasms / therapy
-
Melanoma, Experimental / immunology
-
Melanoma, Experimental / secondary
-
Melanoma, Experimental / therapy
-
Mice
-
Molecular Sequence Data
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / immunology
-
Peptide Fragments / pharmacokinetics
-
Recombinant Fusion Proteins / immunology
-
T-Lymphocytes, Cytotoxic / immunology*
-
Transfection
Substances
-
Antigens, Neoplasm
-
Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome
-
CDC27 protein, human
-
Cancer Vaccines
-
Cell Cycle Proteins
-
Histocompatibility Antigens Class II
-
Peptide Fragments
-
Recombinant Fusion Proteins